Comparative Efficacy and Safety of Interleukin-23 and Interleukin-12/23 Inhibitors in the Induction and Maintenance Phases of Crohn’s Disease: A Systematic Review and Network Meta-Analysis
Open Access
- 5 September 2026
- journal article
- review article
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 81-96
Abstract
Aim. To compare the efficacy and safety of interleukin (IL)-23 and IL-12/23 inhibitors during the induction and maintenance phases of Crohn’s disease using a Bayesian network meta-analysis. Materials and methods. Randomized controlled trials (RCTs) comparing guselkumab (GUS), risankizumab (RIS), ustekinumab (UST), mirikizumab (MIR), briakinumab (BRI), brazikumab (BRA), apilimod mesylate (API) and placebo (PBO) were analyzed. Outcomes included clinical and endoscopic remission/response, adverse events (AEs), and serious adverse events (SAEs). Bayesian random-effects models were used to estimate pooled odds ratios (ORs) with 95 % credible intervals (CrIs). Treatment rankings were determined using the surface under the cumulative ranking curve (SUCRA). Results. Twenty-one RCTs were included. During the induction phase, GUS ranked highest for clinical remission and clinical response, followed by RIS, MIR, and UST, with all agents demonstrating significant efficacy compared with PBO. RIS and MIR achieved significant improvements in endoscopic outcomes over PBO. GUS had the most favorable profile for AEs during induction, whereas RIS achieved greatest reduction in SAEs. During the maintenance phase, RIS was the only agent with demonstrated statistically significant efficacy for clinical remission compared with PBO. No agent achieved statistically significant endoscopic outcomes during maintenance; nevertheless, MIR and GUS ranked highest. Rates of AEs and SAEs were comparable across all active treatments. Conclusion. Guselkumab and risankizumab emerged as the most efficacious and safest IL-23 inhibitors for induction therapy, whereas risankizumab demonstrated the most sustained efficacy in maintenance phase.Keywords
This publication has 38 references indexed in Scilit:
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyThe Lancet, 2024
- EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIESGastroenterology, 2024
- Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn’s Disease: A Systematic Review and Network Meta-AnalysisClinical Gastroenterology and Hepatology, 2024
- Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn’s Disease: Systematic Review and Meta-AnalysisDigestive Diseases and Sciences, 2023
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialThe Lancet, 2022
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsThe Lancet, 2022
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysisThe Lancet Gastroenterology & Hepatology, 2021
- MetaInsight: An interactive web‐based tool for analyzing, interrogating, and visualizing network meta‐analyses using R‐shiny and netmetaResearch Synthesis Methods, 2019
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyThe Lancet, 2017
- Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's diseaseInflammatory Bowel Diseases, 2009